In this study, doctors from France identified factors which predicted a response to azathioprine or 6-mercaptopurine in patients with perianal Crohn's disease.
The team assessed 94 patients (65 female, mean age 31 years) with active perianal Crohn's disease.
Patients were treated with azathioprine or 6-mercaptopurine for more than 6 months.
|29% of patients were responders.|
|Diseases of the Colon and Rectum|
The evolution of perianal lesions during treatment was analyzed retrospectively.
The team considered patients who had a clear anatomic improvement and who did not develop any perianal complications as responders.
The team found that after 3 years, the cumulative probabilities of remaining free of perianal complications and achieving a clear anatomic improvement were 0.47 and 0.4, respectively.
They determined that 29% of patients were responders to azathioprine or 6-mercaptopurine therapy.
The doctors identified the absence of fistula, duration of perianal disease shorter than 22 months, and age ≥40 years at inclusion as factors associated with response to therapy.
There was no correlation between the response of perianal lesions and the achievement of intestinal remission with azathioprine or 6-mercaptopurine.
Dr Thierry Lecomte's team concluded, "One-third of patients with perianal lesions of Crohn's disease demonstrated a clear improvement during azathioprine or 6-mercaptopurine therapy".
"Patients aged 40 years or older with a recent perianal disease and without fistula were the best responders".